| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 May 2024 | 20 May 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve the Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended 31st March 2024 The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2024 at their meeting held on May 28, 2024. This is to inform you that the Board of Director in their meeting held on Tuesday, May 28, 2024 considered and approved the appointment of Mr.Kashinath Sahu as Secretarial Auditor of the Company and T.N. Raghavendra as Internal Auditor of the Company. Read less.. (As Per BSE Announcement Dated on 28.05.2024) | ||
| Board Meeting | 23 May 2024 | 23 May 2024 |
| This is to inform you that the Board of Directors of our material subsidiary Adita Bio Sys Private Limited in their meeting held on Thursday, 23rd May 2024, considered and approved the appointment of Mr.Methuku Nagesh (DIN: 01634324) as an Independent Director, Dr. Prasad S (DIN: 0009659723) as Non executive Non Independent Director and Mr.Balagangadhara B.C. (DIN: 0009658079) as Non Executive Non Independent Director of the Company subject to approval of members of the Company at the ensuing Annual General Meeting. Further the Board of Directors also noted the resignations of Mr.Samuel Sharmanraj Sourappa (DIN: 7004978), Mr. Chetan Basavaraju (DIN: 8154725) and Mr.Kondapura Jayadevappa Shivakumar (DIN: 10249553) from the positions of the Directors of the Company This is to inform you that the Board of Directors of our material subsidiary Adita Bio Sys Private Limited in their meeting held on Thursday, May 23, 2024 considered and approved Mr.Kashinath Sahu as Secretarial Auditor of the Company for the Financial Year 2024-25. (As Per BSE Announcement Dated on 24/05/2024) | ||
| Board Meeting | 2 Mar 2024 | 2 Mar 2024 |
| We hereby inform that Board of Directors of the Company at its meeting held today i.e; March 02, 2024, approved the allotment of 1,28,56,578 fully paid up Equity Shares for the Consideration other than cash on Preferential Basis by way of Private Placement. We hereby inform that Board of Directors of the Company at its meeting held today, i.e, March 02, 2024 approved the allotment of 12856578 fully paid-up Equity Shares for the Consideration other than cash on Preferential Basis by way of Private Placement. The details as required under Regulation 30 of Listing Regulations read with SEBI Circular dated July 13, 2023 are given in the attached intimation. | ||
| Board Meeting | 12 Feb 2024 | 2 Feb 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended 31st December 2023. The Board at its meeting held on 12th February 2024, have considered declaration of financial results for the quarter and nine months ended 31st December 2023 amongst other important matters. (As Per BSE Announcement Dated on: 12/02/2024) | ||
| Board Meeting | 6 Jan 2024 | 3 Jan 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the meeting of the Borad of Directors of the Company is scheduled to be held on Saturday 06th January 2024. Outcome of the Board meeting held on saturday, 06 January 2024. (As per BSE Announcement Dated on 06/01/2024) This is to inform you that Board of Directors in their meeting held on Saturday, 06, 2024, considered and approved the appointment of Dr. Shankarappa Vinaya Babu (DIN:01373832) as Director and Chairman (Non-Executive & Non-Independent) of the Company subject to the approval of the members of the company at the ensuing General Meeting of the Company. Further, Board of Directors has approved the appointment of Dr. Prasad S as Chief Executive Officer (CEO) of the company in the category of Key Managerial Personnel. Outcome of the Board meeting held on saturday, 06 January 2024. (As per BSE Announcement Dated on 06/01/2024) Intimation of Alteration in Object Clause and Capital Clause of the Memorandum of Association of the Company. (As Per BSE Announcement dated on 07.01.2024) Further to our intimation dated 06th January 2024, The Company has executed agreements with the shareholders for purchase of shares of Adita Bio Sys Private Limited. (As Per BSE Announcement Dated on 09.01.2024) | ||
| Board Meeting | 11 Nov 2023 | 4 Nov 2023 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2023. Outcome of the Board Meeting held on 11th September , 2023 for approval of unaudited Standalone and Consolidated financial results for the quarter and half year ended 30th September 2023. (As Per BSE Announcement dated on 11.11.2023) | ||
| Board Meeting | 29 Aug 2023 | 22 Aug 2023 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2023 inter alia to consider and approve the Audited Financial Statements (Standalone & Consolidated) for the year ended 31st March 2023 the Directors Report for the year ended 31st March 2023 To appoint a Scrutinizer to ascertain Voting Process of 34th Annual General Meeting of the Company To approve draft Notice of 34th Annual General Meeting (AGM) and to decide the date time and venue of the AGM To consider and fix Record date and/or Book closure date for the purpose of 34th Annual General Meeting. Outcome of the Board Meeting held on 29th August , 2023 for approval of Annual Financial Statements for the financial year 2022-23 and AGM related matters. Disclosure under Regulation 30 of SEBI Listing Regulations, 2015. the Baord in its meeting held on 29th Aug 2023, approved the appointment of Mr. Shreedhara Shetty, as Additonal Director in the Category of Non-executive Non-independent Director, Considered resignation of Mr. Venkata Rao Sadhanala as Non-executive Non-Independent Director, Re-appointment of PPKG & Co., Chartered Accountants as Statutory Auditors of the Company. (As Per BSE Announcement Dated on 29/08/2023) | ||
| Board Meeting | 4 Aug 2023 | 28 Jul 2023 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023 inter alia to consider and approve Unaudited Financial Results for the quarter and three months ended 30th June 2023. PHARMAIDS PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 04 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. (As Per BSE Announcement Dated on 01/08/2023) Outcome of the Board Meeting held on 04th August , 2023 for approval of unudited Standalone and Consolidated financial results for the quarter ended 30th June 2023. M/s Kashinath Sahu & Co., Practicing Company Secretaries has been re-appointed as a secretarial auditor of the company for the financial year 2023-2024. Pursuant to the provisions of regulation 30 and 31A(8) of the Listing Regulations, we wish to inform you that the board at its meeting held today, i.e., 04th August 2023, has inter alia considered and approved the request for reclassfication of Five promoters from Promoter/promoter Category to Public Category. Details of which is provided in the enclosed minutes. (As per BSE Announcement Dated on 04/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
